Buhl R - Search Results

1

One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β₂-agonist in UK primary care settings.

Buhl R, Heaney LG, Loefroth E, Larbig M, Kostikas K, Conti V, Cao H. Buhl R, et al. Respir Med. 2020 Feb;162:105859. doi: 10.1016/j.rmed.2019.105859. Epub 2019 Dec 30. Respir Med. 2020. PMID: 31916534 Free article.

2

Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease.

Beeh KM, Kornmann O, Beier J, Ksoll M, Buhl R. Beeh KM, et al. Among authors: buhl r. Respir Med. 2004 Jul;98(7):591-7. doi: 10.1016/j.rmed.2004.01.004. Respir Med. 2004. PMID: 15250223 Free article.

3

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.

Korn S, Buhl R. Korn S, et al. Among authors: buhl r. Respir Med. 2012 Jan;106(1):57-67. doi: 10.1016/j.rmed.2011.08.010. Epub 2011 Sep 3. Respir Med. 2012. PMID: 21890335 Free article. Clinical Trial.

4

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy.

Buhl R, Kuna P, Peters MJ, Andersson TL, Naya IP, Peterson S, Rabe KF. Buhl R, et al. Respir Res. 2012 Jul 20;13(1):59. doi: 10.1186/1465-9921-13-59. Respir Res. 2012. PMID: 22816878 Free PMC article. Clinical Trial.

5

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R. Korn S, et al. Among authors: buhl r. Respir Med. 2012 Nov;106(11):1494-500. doi: 10.1016/j.rmed.2012.07.010. Epub 2012 Aug 11. Respir Med. 2012. PMID: 22884459 Free article. Clinical Trial.

6

Eligibility for treatment with omalizumab in Italy and Germany.

Buhl R, Marco AG, Cohen D, Canonica GW. Buhl R, et al. Respir Med. 2014 Jan;108(1):50-6. doi: 10.1016/j.rmed.2013.10.026. Epub 2013 Nov 9. Respir Med. 2014. PMID: 24315468 Free article.

7

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.

Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, Fogel R, Banerji D. Wedzicha JA, et al. Among authors: buhl r. Respir Med. 2014 Oct;108(10):1498-507. doi: 10.1016/j.rmed.2014.07.011. Epub 2014 Aug 4. Respir Med. 2014. PMID: 25135743 Free article. Clinical Trial.

8

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.

Wedzicha JA, Buhl R, Lawrence D, Young D. Wedzicha JA, et al. Among authors: buhl r. Respir Med. 2015 Jan;109(1):105-11. doi: 10.1016/j.rmed.2014.10.011. Epub 2014 Oct 27. Respir Med. 2015. PMID: 25433954 Free article.

9

Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R. Timmer W, et al. Among authors: buhl r. Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27. Respir Med. 2015. PMID: 25661281 Free article. Clinical Trial.

10

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.

Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P. Mahler DA, et al. Among authors: buhl r. Respir Med. 2015 Aug;109(8):1031-9. doi: 10.1016/j.rmed.2015.05.012. Epub 2015 May 22. Respir Med. 2015. PMID: 26094050 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

558 results

Search Page

Filters